The role of Inil in chromatin development and cancer
Project Number5R01CA095216-02
Contact PI/Project LeaderJONES, STEPHEN
Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
DESCRIPTION: (provided by applicant) Inil is a subunit of the mammalian,
ATP-dependent, SWI/SNF chromatin remodeling complexes. These enzymes play a key
role in cell growth by altering chromatin structure to render normally
condensed DNA accessible to cellular machinery, an important preliminary step
to facilitate gene expression, cell division, and development. Subunits of the
SWI/SNF enzymes interact with Rb and BRCA-l, known tumor suppressor proteins.
The recent identification of Ini1 mutations in familial malignant rhabdoid
tumors has further heightened interest in the link between SWI/SNF complexes
and tumor suppression. Previous work from our labs has identified and
characterized mammalian SWI/SNF complexes as possessing ATP dependent chromatin
remodeling activities and has identified a role for SWI/SNF chromatin
remodeling in differentiation of muscle as well as other differentiation
events. Recently, we have generated mice deficient for Ini and have found that
Inil is required for proper early embryogenesis, and tumor formation in
Inil-haploinsufficient mice has identified Inil as a bonajide tumor suppressor
in mice. The research described in this proposal will draw upon the strengths
of the two investigators, utilizing a combination of genetic, biochemical, and
molecular approaches to elucidate the mechanistic role of Inil in
transformation and differentiation. Additionally, these studies will examine
the role of Ini chromatin remodeling enzymes. Mice heterozygous for Inil will
be treated with DNA damaging agents, and will be bred to mice bear mg
inactivated alleles of the p53 gene or the Rb gene to investigate the link
between the Inil-based SWI/SNF activity and DNA damage repair pathways, and to
explore the role of the two major tumor suppressor pathways in Inil-mediated
tumor suppression. Mice bearing a conditional allele of Ini1 will also be
generated via gene targeting experiments in ES cells. The specificity of the
site of tumorigenesis in the Inil-deficient mice is striking; 100 percent of
the tumors arise on the face, head, and neck of the mouse, whereas in humans
bearing an inactivated Ini1 gene, most of the tumors arise in the kidney and/or
brain. Interestingly, these structures are all derived from neural crest
progenitor cells during development. In order to determine if tumorigenesis in
the Inil mice is due to a defect in neural crest cell growth or
differentiation, the conditional Inil mice will be bred with mice expressing
Cre specifically in neural crest cells. The conditional Inil mice also will be
crossed with mice expressing the Cre recombinase in cardiac and skeletal muscle
in order to provide in vivo evidence for a link between SWI/SNF activity and
muscle cell differentiation. Lastly, we will purify SWI/SNF complexes from
Inil-deficient cells. Isolated purified protein will be characterized for
subunit composition and the ability to interact with tumor suppressor proteins.
Furthermore, we will assess the ability of purified complexes/subunits lacking
Ini1 to remodel chromatin structure and induce specific gene activation events
in vitro. These proposed experiments should serve not only to define the role
of Inil in differentiation and chromatin remodeling, but should also provide
much insight into the mechanisms of Inil-mediated tumor suppression.
No Sub Projects information available for 5R01CA095216-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA095216-02
Patents
No Patents information available for 5R01CA095216-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA095216-02
Clinical Studies
No Clinical Studies information available for 5R01CA095216-02
News and More
Related News Releases
No news release information available for 5R01CA095216-02
History
No Historical information available for 5R01CA095216-02
Similar Projects
No Similar Projects information available for 5R01CA095216-02